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There is growing evidence of a significant burden of human papillomavirus (HPV) infection and associated disease in men. 
High rates of HPV infection have been observed in men from sub-Saharan Africa where HIV prevalence is high. HIV infection 
increases HPV prevalence, incidence and persistence and is strongly associated with the development of anogenital warts and 
anal, penile and head and neck cancers in men. Despite increasing access to antiretroviral therapy, there appears to be little 
benefit in preventing the development of these cancers in HIV-positive men, making prevention of infection a priority. New 
prevention options that are being introduced in many African countries include male circumcision and HPV vaccination. 
However, more data are needed on the burden of HPV disease in men before boys are included in HPV vaccination programmes.
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Human papillomavirus (HPV) is a common 
sexually transmitted infection (STI) affecting 
both men and women.[1] HPV infections can be 
classified as either low- (LR) or high-risk (HR). [2] 
HR-HPV infections have been associated 
with cancer of the anogenital and oropharyngeal tissues. 
While the majority of HPV infections are transient and clear 
spontaneously, persistent infection with HR-HPV is associated 
with the development of pre-neoplastic and neoplastic lesions 
in these areas (Fig. 1). While much is known about the natural 
history of HPV infection in cervical cancer in women, less is 
known about the development of HPV-associated disease 
in men. Emerging evidence points to a significant role for 
HIV infection in promoting HPV prevalence, incidence and 
persistence. This review provides an update on current evidence 
regarding the epidemiology of HPV infection and disease in 
men, the effects of HIV on HPV infection and disease in men 
in sub-Saharan Africa (SSA), and the prospects for prevention 
in this setting. 
Global burden of HPV
HPV infection is ubiquitous in men. A systematic review of 
62 studies using reliable methods of HPV DNA detection 
and conducted prior to 2009, representing 14 800 men in 23 
countries, showed that anogenital HPV DNA prevalence is 
generally high in sexually active men. The review highlighted 
considerable variation in estimates by region, from 1% to 
84% in LR men, to 2% to 93% in HR men.[3] Compared with 
studies in women, peak prevalence spanned a wide range of 
ages, suggesting that men have the potential for longer-term 
persistence of infection or higher rates of re-infection.[3] Type-
specific HPV seroprevalence studies are better indicators 
of lifetime exposure to HPV infection, although they may 
underestimate cumulative HPV exposure, given that not all 
infections lead to seroconversion.[4] Recent population-based 
studies have estimated the prevalence of antibodies to vaccine-
preventable HPV types 6, 11, 16 and 18. Among men aged 14 
- 59 years in the USA, 12.2% of men were seropositive for any 
vaccine type, with a peak prevalence of 18% among men aged 
50 - 59 years.[5] In a similar population-based study in Australia, 
peak prevalence of any vaccine type was 31.5% among men aged 
40 - 49 years;[6] and a study from the Netherlands estimated that 
the seroprevalence of any HR-HPV in men aged ≥14 years was 
20%.[7] There is some evidence that seroprevalence appears to 
be rising as a result of changes in sexual behaviour and earlier 
age of sexual debut. In a related study from the Netherlands 
comparing serosurveillance rates of HR-HPV in the periods 
1995 - 1996 and 2006 - 2007, overall HR-HPV seroprevalence 
rates were significantly higher in the later survey, compared with 
the earlier survey across all age groups.[8] 
Burden of infection in SSA
A recent global review of 117 studies worldwide suggests that 
the seroprevalence of HPV is even higher in SSA, although 
data on men in SSA are sparse.[4] In a small study of Tanzanian 
genital ulcer disease (GUD) patients, pregnant women and 
male blood donors, the prevalence of antibodies to HR-HPV 
ranged from 77% in male GUD patients to 15% in male blood 
donors. In this study, the prevalence of antibodies to HPV 
types 16, 18, 51 and 52 was considerably higher in HIV-positive 
patients with GUD.[9] 
Although data on anogenital HPV DNA prevalence in 
men in SSA are also limited,[3] overall reported prevalences 
in men are high, ranging from 19% to 78%.[10-15] In most, 
but not all studies, the most prevalent type was HPV-16.[15] 
The observed heterogeneity in estimates can be attributed 
to differences in age distribution, sexual behaviour and HIV 
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suggest that the incidence of HR anogenital 
HPV infection in men is also high, ranging 
from 35.7/100 person years in South African 
men to 40/100 person-years in East African 
men participating in male circumcision (MC) 
trials.[16-18] In both settings, the risk of HPV 
acquisition was doubled in HIV-positive men. 
These incidence rates are much higher than 
those previously observed else where.[19,20]
Factors associated 
with HPV infection
HPV seroprevalence rates are consistently 
lower in men than in women,[6,21,22] with men 
also producing lower antibody titres than 
women. [23] There are several plausible bio-
logical explanations for differences in antibody 
responses between men and women. Men may 
experience a higher frequency of transient 
infections, a lower viral load, or produce 
less robust immunological responses than 
women. [24] It has been argued that the site of 
infection and/or type of epithelium influence 
antibody responses, with men experiencing 
a higher proportion of infections in more 
keratinised tissues (e.g. penile shaft) than 
women (e.g. anal canal or cervix). Thicker, 
more keratinised epithelium may present a 
barrier to infection, and if infected, may be 
less likely than mucosal surfaces to induce 
an immune response, given the relative 
distance from draining lymphatics and 
lymph nodes. [23,25] Recent data from a study 
comparing type-specific HPV antibody pre-
valence with the corresponding prevalence of 
HPV DNA detected in the external genitalia 
and anal canal in heterosexual men and men 
who have sex with men (MSM) support this 
notion. Higher HPV-6 and -16 seroprevalence 
rates were observed in men that had a same 
HPV-type infection in the anal canal, than in 
those with the same HPV-type infection in the 
external genitalia only. Higher seroprevalence 
rates were also observed in MSM compared 
with heterosexual men.[26] 
The association between HPV infection 
and age is somewhat inconsistent, with fairly 
flat prevalence curves reported in populations 
where HIV prevalence is relatively low. [3,27] 
Data emerging from Africa, present a simi-
larly mixed picture. A study among Kenyan 
fishermen showed a lower risk for HPV 
infection in older age groups,[10] while data 
from Kenyan men participating in an MC 
trial showed little variation in prevalence 
with age.[28] A more recent study in men 
from Tanzania demonstrated an association 
between increasing age and HPV prevalence, 
but that this association was driven by HIV-
positive men.[15] Two recent incidence studies 
confirmed that increasing age is associated 
with a lower risk for HPV infection.[16,17] 
Combined, these data tend to suggest that 
the association between HPV infection and 
age in men in SSA is related to patterns of 
sexual activity, but confounded by HIV status, 
which may promote the persistence of HPV 
infection. 
Sexual behaviour is an important risk 
factor for anogenital HPV infection. More 
recent publications have highlighted the 
importance of age of sexual debut,[8] marital 
status,[29] high number of lifetime sexual part-
ners,[5,30,31] number of recent sexual partners,[30] 
longer history of sexual activity,[30] route of 
exposure,[26,30,32] and having sex with men[32-34] 
as risk factors for anogenital HPV infection. 
Similar observations about sexual risk 
behaviour and an association with HPV have 
been made in studies of men in SSA.[10,17,28] 
While the data on the protective effects of 
condoms are somewhat mixed,[35] evidence 
from African studies in men show a reduced 
risk of genital HPV infection associated with 
condom use.[10,28,36,37] Evidence from randomised 
controlled trials (RCTs) of MC has conclusively 
demonstrated the protective benefits of MC 
in reducing the risk of HPV prevalence and 
incidence.[17,36,38,39] Related findings from the 
trial in Kenya have highlighted less frequent 
bathing as a risk factor for HPV infection, 
which may be associated with poor genital 
hygiene in uncircumcised men.[18,28] 
STIs are independently associated with 
the risk of HPV infection, particularly chla-
mydia,[19,30] herpes simplex virus (HSV)-2,[34] 
and hepatitis B.[40] While they may share a 
common mode of transmission, STIs are 
thought to increase the risk of HPV infection 
by facilitating access to the basal epithelium 
through micro-abrasions in the skin.[35] Recent 
reports on male populations in Africa point to 
a higher risk of penile HPV in men co-infected 
with laboratory-diagnosed Chlamydia tracho-
matis or Neisseria gonorrhoeae, and those 
who are HSV-2-seropositive.[28] Interestingly, 
HR-HPV clearance was recently shown to 
shown to be higher in HIV-negative men 
co-infected with syphilis or HSV-2, suggesting 
that other genital tract infections may also 
create an inflammatory cytokine milieu that 
may facilitate the clearance of HPV.[17]
HIV is a strong risk factor for HPV infection 
in men. While studies of anal HPV infection 
in MSM from Europe and the Americas first 
identified an increased risk for infection in 
HIV-positive men,[24] there is now a growing 
body of evidence from studies of men in SSA 
that shows that prevalent and incident ano-
genital HPV infection is more common in 
HIV-positive men.[15,16,37] Multiple infections, 
particularly with HR-HPV, are more common 
in HIV-positive men.[13,41] Prevalence of infec-
t ion increases with declining CD4+ count.[42] 
Partner HIV status has also been shown to 
increase the risk of HPV detection in men.[14,43] 
Anogenital warts
Anogenital warts (AGWs) are the most 
common clinical manifestation of HPV infec-
tion.[44] Caused mainly by infection with HPV-6 
and -11,[45] they are highly infectious. An esti-
mated 65% of people whose sexual partner has 
genital warts will develop warts themselves. [46] 
The estimated incubation period from HPV 
infection to genital wart development is 2 
weeks - 8 months.[47] While approximately 
20 - 30% of genital warts will spontaneously 
regress,[48] recurrence is common, resulting in 
significant psychological morbidity and high 
medical costs for repeated treatment. These 
costs are not insignificant when compared 





















with costs for treatment of cervical cancer 
in women.[49] Two recent reviews estimated 
the prevalence and incidence of AGWs in 
the general adult population worldwide[45] 
and in SSA,[50] respectively.. Worldwide, the 
overall prevalence of AGWs, based on genital 
examinations, ranged from 0.2% to 5.1%, with 
higher prevalence rates observed in males. Data 
suggest that prevalence has increased in recent 
decades, possibly as a result of changes in sexual 
behaviour. 
Studies in male populations in SSA suggest 
much higher prevalence rates than in high-
income countries, possibly as a result of 
higher HIV prevalence rates. Highest rates of 
4.8 - 12.2% have been observed in HR men 
from Central and South Africa, a region of 
high HIV prevalence. Lack of circumcision 
and HIV infection have been identified as risk 
factors for AGWs in men.[12] Importantly, HIV-
positive men with AGWs may also be at risk 
for infection with HR-HPV. In a small study 
in Johannesburg among HIV-positive men 
with penile warts, 85% were found to have 
HR-HPV as well. HPV-16 and -18 were most 
frequently detected.[41] These high rates of 
HR-HPV detection in men with HIV suggest 
that they are at significant risk for the future 
development of pre-neoplastic and neoplastic 
lesions, emphasising the importance of target-
ing screening programmes for HIV-positive 
men with AGWs. 
Anal cancer
While relatively uncommon, the incidence 
of anal cancer in men appears to be rising.[51] 
A systematic review examined these trends, 
and found that age-adjusted incidence rates 
for anal cancer have increased in several 
high-income countries, with HPV infection 
identified as the most important associated 
aetiological factor.[52] Besides increasing 
age, smoking, receptive anal intercourse 
and HIV infection were the most important 
risk factors for anal cancer, with the highest 
incidence rates observed in HIV-positive 
MSM. While anal cancer incidence is highest 
in HIV-positive MSM, it should be noted that 
receptive anal intercourse is not a prerequisite 
for anal HPV infection, pre-cancer lesions or 
anal cancer. Piketty et al.[53] demonstrated 
high rates of anal infection and squamous 
intraepithelial lesions in HIV-positive men 
with no previous history of anal intercourse 
– an observation made subsequently in 
other studies.[54] In such instances, anal HPV 
infection is thought be transferred to the anal 
canal through transiently infected fingers 
or toys, as well as by shedding from other 
infected genital sites.
Anal cancer is considered to be biologic-
ally similar to cervical cancer. Like cervical 
cancer, it is thought to be preceded by a 
spectrum of intraepithelial changes and anal 
intraepithelial neoplasia (AIN), which can 
be graded similarly to cervical cancer. While 
there is strong supportive evidence that 
high-grade AIN is a precursor to invasive 
cancer, there is no consensus regarding the 
prevalence or significance of AIN, nor on the 
rate of AIN progression to cancer. Almost all 
of the natural history data come from studies 
in MSM, with few data on heterosexual, HIV-
negative or African populations. A recent 
meta-analysis of anal HPV and associated 
lesions in MSM found that HIV-positive men 
were consistently more likely to be infected 
with HPV, to have associated lesions, and 
to have higher rates of anal cancer, although 
the excess in HIV-positive men was smallest 
for high-grade AIN, and was not statistically 
significant for that category. While there were 
no data on progression rates of AIN to cancer, 
estimates from this analysis suggest that 
rates of progression are significantly lower 
than those observed in cervical cancer.[55] 
Despite significant heterogeneity in the data, 
and a lack of prospective data, it remains 
plausible that high-grade AIN lesions regress 
more frequently than high-grade cervical 
lesions. [56] While the prevention of anal 
cancers in high-risk HIV-positive men is a 
priority, these findings raise doubts about the 
utility of anal cancer screening programmes 
at present. Until further evidence of benefit 
for screening in terms of reductions in anal 
cancer incidence and mortality become 
available, anal cancer screening programmes 
for men are likely to be controversial.
Despite immune reconstitution associated 
with highly active antiretroviral therapy 
(HAART), there appears to be little evidence 
that this therapy has a preventive effect on the 
development of anal cancer. The recent meta-
analysis and other analyses of temporal trends 
in anal cancer incidence have highlighted the 
continuing high incidence of anal cancer, despite 
the widespread introduction of HAART. [55,57,58] 
These data suggest that prolonged survival 
afforded by HAART initiation may allow more 
time for AIN to progress to cancer, thus leading 
to higher anal cancer rates.
Penile cancer
Penile cancers are relatively rare. In 2008, of the 
estimated 22 000 new penile cancer cases, half 
were attributable to HPV, with much higher 
rates observed in regions with a low human 
development index.[59] Data from Zimbabwe 
suggest that southern Africa has higher 
incidence rates,[60] and a recently published 
report of HPV detection in cancerous and pre-
cancerous penile lesions from men in South 
Africa demonstrated multiple HPV infections, 
with high rates of HPV-16.[61] Risk factors for 
penile cancer include: a lack of MC; phimosis 
and/or poor genital hygiene; AGWs; and HIV 
infection. HIV-positive men have an eight-fold 
increased risk of penile cancer, which may be 
associated with higher HPV infection rates.[62] 
Other risk factors for penile cancer that have 
been reported include current smoking, early 
age of first sexual intercourse, high lifetime 
number of female sexual partners, lack of 
condom use, chronic inflammatory conditions 
including balanitis and lichen sclerosus, and 
treatment with ultraviolet photochemotherapy 
for psoriasis.[63] 
Head and neck 
squamous cell 
carcinomas
Head and neck cancer commonly refers to 
squamous cell carcinomas (SCCs) arising 
in the upper aerodigestive tract (oral cavity, 
nasopharynx, hypopharynx and larynx). 
Traditionally, most head and neck cancers 
were associated with tobacco and alcohol 
exposures and presented after the age 
of 60 years. More recently, a shift in the 
epidemiology of oropharyngeal SCC has been 
observed, with a rising incidence, particularly 
in the palatine tonsils and base of the tongue, 
occurring in younger age groups and in people 
who have never smoked. [64] Like the cervix 
and anus, there is an epithelial transition zone 
within the oropharynx which is prone to HPV 
infection, dysplasia and the development 
of SCCs. In a systematic review of studies 
involving histological specimens of head and 
neck SCCs, in 36% HPV DNA was detected, 
and HPV-16 was the most common HPV 
type associated with head and neck SCC.[65] 
HIV-infected individuals have a 1.5 - four-
fold higher risk of oropharyngeal or tonsillar 
cancer than the general population. Although 
the proportion of oropharyngeal cancers is 
unknown, HIV-positive individuals appear 
to be at moderately increased risk of HPV-
associated head and neck SCC compared 
with the general population.[66] D’Souza et 
al.[67] showed convincing evidence that oral 
cavity HPV DNA infection was related to 









evidence that HIV-positive individuals have a higher prevalence of oral 
HR-HPV, even after controlling for sexual behaviour,[68] and that the risk 
for infection appears to be higher among those with a declining CD4+ 
count.[69] While there are limited data on the natural history of oral HPV 
infection, the majority of infections clear within two years,[70] although 
persistence appears to be associated with a CD4+ count <500 cells/μl.[71] 
There do not appear to be benefits for HAART on either the persistence 
of HPV infection or the clearance of oral lesions, but more evidence is 
needed in this regard.[66] Data on oral HPV and HPV-associated head 
and neck SCC in African populations is currently scarce, although 
one study from Senegal,[72] which included 117 invasive head and neck 
cancer histology specimens, mainly from men with a mean age of 
52 years, found only four cases to be positive for HPV DNA. The authors 
remarked that larger studies are needed to confirm these findings and 
explore other potential risk factors specific to the region.[72]
Prevention of HPV-associated 
infection and disease in men 
Evidence for the benefit of several strategies to prevent HPV infection 
and subsequent disease in men has emerged in recent years. Studies 
have shown a greater protective effect of condoms in the prevention of 
HPV acquisition in men. Analysis of data from a multi-national cohort 
study in men showed a two-fold lower risk of HPV acquisition in men 
with no steady partner and who always used condoms. In addition, the 
probability of clearing an oncogenic infection was 30% higher in men 
who consistently used condoms with non-steady partners.[73] Consistent 
condom use has also been associated with the regression of penile 
lesions in men.[74] Recent RCTs in Africa provide strong evidence that 
MC is protective against HPV infection. In these trials, MC has been 
associated with reductions in the incidence, prevalence and persistence 
of HPV infection in men. In HIV-negative men, MC has also been 
shown to reduce HR-HPV transmission to female partners.[75] Recent 
data suggests that decreased penile shedding of HR-HPV observed 
in HPV-infected circumcised men may help to explain the protective 
effects observed for female partners.[38] MC has also been associated 
with a lower prevalence of flat penile lesions in men.[39] 
Vaccines are the ideal form of primary prevention for infectious 
diseases, and have been successful in the control of many other infectious 
diseases. Having been shown to be efficacious in women, HPV vaccine 
studies have now demonstrated evidence of benefit in men. An RCT 
involving 4 065 men from 18 countries aged 16 - 26 years showed that 
the quadrivalent vaccine was 90% effective in preventing infection with 
vaccine-specific types in the per protocol analysis, and 89% effective in 
preventing AGWs in the same population.[76] In 602 MSM aged 16 - 26 
years, the quadrivalent vaccine was 77.5% effective in preventing HPV-6-, 
-11-, -16- and -18-associated AIN.[77] The bivalent vaccine is not currently 
registered for use in men. HPV vaccination has been shown to be safe and 
highly immunogenic in HIV-1 infected men.[78] Modelling studies predict 
benefits of vaccination for boys, when high levels of vaccine coverage are 
achieved in girls,[79] and data emerging from countries where national 
vaccination programmes have been introduced confirm this. Even 
though vaccination was restricted to girls, in Australia, there has been an 
82% decline in AGWs in men aged <21 years since the introduction of 
the vaccine.[80] In Denmark, a 50% decline in AGWs in young men aged 
<19 years was observed only three years post vaccine introduction. [81] 
However, these benefits may not translate to all men, particularly MSM 
who may not benefit from herd immunity. Australia is the first country 
to extend vaccination to men. While several countries in Africa have 
recently introduced HPV vaccination programmes, these school-based 
programmes do not include boys. Further evidence is needed of the 
HPV-associated burden of disease in men, and the potential effects of 
HIV on HPV-associated disease in men before the vaccination of boys 
can be considered in lower-resource settings. 
Conclusion
HPV infection and associated disease are common in men in SSA. 
While data on the burden of disease are limited, studies suggest that 
infection with HPV is common, particularly in the context of HIV. 
There is also growing evidence to suggest that HIV infection enhances 
HPV persistence – a precursor for the development of cancer. Given 
expanding access to HAART in Africa, there is now potential for 
significant morbidity and mortality from HPV-related cancers in 
men in the future. While MC and HPV vaccination programmes are 
being rolled out in many African countries where the burden of HIV 
is high, more data are needed on the natural history and burden of 
HPV-associated disease in men in Africa to inform the development of 
prevention programmes. 
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